- The Food and Drug Administration on Monday sent a warning letter to Curaleaf, telling the company that it is illegally marketing cannabidiol, or CBD, products as medicines.
- The regulatory sanction sent shares in the company, one of the largest in the booming cannabis market, down sharply. By law, Curaleaf products like CBD Lotion, CBD Pain-Relief Path and CBD Disposable Vape Pen are unapproved drugs, the FDA said.
- “Failure to correct the violations promptly may result in legal action, including product seizure and injunction,” the agency said in an accompanying statement issued Tuesday.
Curaleaf is the latest cannabis company to get caught up in the confusion over CBD products regulations. Congress last year passed a bill that legalized hemp, a form of cannabis that doesn’t get users high. But many people believe that CBD, derived from hemp, has medicinal potential.
The problem is the FDA has yet to offer